• 1-800-526-8630U.S. (TOLL FREE)
  • 1-917-300-0470EAST COAST U.S.
  • +353-1-416-8900REST OF WORLD
Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2011 - Product Image

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2011

  • ID: 1931515
  • September 2011
  • 116 pages
  • Global Markets Direct

Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2011', provides an overview of the Type 1 Diabetes (Juvenile Diabetes) therapeutic pipeline. This report provides information on the therapeutic development for Type 1 Diabetes (Juvenile Diabetes), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Type 1 Diabetes (Juvenile Diabetes). 'Type 1 Diabetes (Juvenile Diabetes) - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Type 1 Diabetes (Juvenile READ MORE >

Note: Product cover images may vary from those shown



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Type 1 Diabetes (Juvenile Diabetes) Overview
Therapeutics Development
An Overview of Pipeline Products for Type 1 Diabetes (Juvenile Diabetes)
Type 1 Diabetes (Juvenile Diabetes) Therapeutics under Development by Companies
Type 1 Diabetes (Juvenile Diabetes) Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Type 1 Diabetes (Juvenile Diabetes) Therapeutics - Products under Development by Companies
Type 1 Diabetes (Juvenile Diabetes) Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Type 1 Diabetes (Juvenile Diabetes) Therapeutics Development
Osiris Therapeutics, Inc.
Sanofi-Aventis
Eli Lilly and Company
Altea Therapeutics Corporation
Inovio Biomedical Corporation
MedImmune LLC
Taisho Pharmaceutical Co., Ltd.
Novo Nordisk A/S
Takeda Pharmaceutical Company Limited
Novartis AG
Biocon Limited
Hadasit Medical Research Services & Development Ltd
NephroGenex, Inc.
AutoImmune Inc.
Biodel Inc.
Geron Corporation
MannKind Corporation
Halozyme Therapeutics
Evotec Aktiengesellschaft
Living Cell Technologies Limited
MultiCell Technologies, Inc.
Oramed Pharmaceuticals, Inc.
MAP Pharmaceuticals, Inc.
Flamel Technologies S.A.
Tolerx, Inc.
XOMA Ltd.
Lipoxen PLC
SemBiosys Genetics Inc.
Uni-Bio Science Group Ltd.
Kamada Ltd.
DiaMedica Inc.
CPEX Pharmaceuticals, Inc.
Affimed Therapeutics AG
Bayhill Therapeutics, Inc.
Phosphagenics Limited
Artielle ImmunoTherapeutics, Inc.
ApoImmune, Inc.
DiaKine Therapeutics, Inc.
Peptimmune, Inc.
Kineta, Inc.
Creative Peptides Sweden AB
Andromeda Biotech Ltd.
AIM Therapeutics Inc.
NovImmune SA
Txcell SA
TcL Pharma SAS
Versartis, Inc.
Virobay Inc.
Immunomod, LLC
Exsulin Corporation
REGiMMUNE Corporation
TikoMed AB
Adocia
Diasome Pharmaceuticals, Inc.
PharmaIN Corporation
Type 1 Diabetes (Juvenile Diabetes) - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles
Teplizumab - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Otelixizumab - Drug Profile
Degludecplus - Drug Profile
DiaPep277 - Drug Profile
AI401 - Drug Profile
Afrezza - Drug Profile
Degludec - Drug Profile
Kineret - Drug Profile
Lantus - Drug Profile
NPH Insulin - Drug Profile
Insulin + Symlin - Drug Profile
Insulin + Byetta - Drug Profile
LY041001 - Drug Profile
Linjeta - Drug Profile
Liraglutide - Drug Profile
Oral HDV-Insulin - Drug Profile
Technosphere Insulin + Lantus - Drug Profile
Pramlintide - Drug Profile
Ergocalciferol - Drug Profile
Atorvastatin - Drug Profile
Autologous Transplantation Of Bone Marrow Mesenchymal Stem Cells - Drug Profile
Humalog + Lantus - Drug Profile
Insulin + Metformin - Drug Profile
NN1250 + Insulin Aspart - Drug Profile
Type 1 Diabetes (Juvenile Diabetes) Therapeutics – Drug Profile Updates
Type 1 Diabetes (Juvenile Diabetes) Therapeutics - Discontinued Products
Type 1 Diabetes (Juvenile Diabetes) - Featured News
Aug 05, 2011: Orban Biotech Presents Abatacept Data At American Diabetes Association Meeting
Aug 04, 2011: Kamada Receives New Orphan Drug Designation From FDA For Treatment Of Type 1 Diabetes
Aug 04, 2011: Kamada Was Granted New Orphan Drug Designation by the FDA, For The Treatment of Type 1 Diabetes
Jun 28, 2011: TrialNet Presents Results From Study With Diamyd
Jun 28, 2011: MacroGenics Announces Publication Of Protege Phase III Clinical Data Of Teplizumab In The Lancet
Jun 27, 2011: Novo Nordisk's Degludec Reduces Hypoglycaemia And Improves Long-Term Control In Patients With Type 1 And Type 2 Diabetes
Jun 27, 2011: LCT Enrols First Patients In Phase II DIABECELL Argentina Trial
Jun 27, 2011: Adocia Launches Phase IIa Clinical Study on Type 1 Diabetic Patients With Its Fast-acting Human Insulin, HinsBet(R)
Jun 24, 2011: Studies Show No Increased Risk Of Cardiac Events In Diabetes Patients Treated With AFREZZA
Jun 24, 2011: Halozyme's Ultrafast Insulin Demonstrates Reduced Variability Of Insulin Absorption For Type 1 Diabetes Patients Using Insulin Pumps
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2011
Products under Development for Type 1 Diabetes (Juvenile Diabetes) – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Osiris Therapeutics, Inc., H2 2011
Sanofi-Aventis, H2 2011
Eli Lilly and Company, H2 2011
Altea Therapeutics Corporation, H2 2011
Inovio Biomedical Corporation, H2 2011
MedImmune LLC, H2 2011
Taisho Pharmaceutical Co., Ltd., H2 2011
Novo Nordisk A/S, H2 2011
Takeda Pharmaceutical Company Limited, H2 2011
Novartis AG, H2 2011
Biocon Limited, H2 2011
Hadasit Medical Research Services & Development Ltd, H2 2011
NephroGenex, Inc., H2 2011
AutoImmune Inc., H2 2011
Biodel Inc., H2 2011
Geron Corporation, H2 2011
MannKind Corporation, H2 2011
Halozyme Therapeutics, H2 2011
Evotec Aktiengesellschaft, H2 2011
Living Cell Technologies Limited, H2 2011
MultiCell Technologies, Inc., H2 2011
Oramed Pharmaceuticals, Inc., H2 2011
MAP Pharmaceuticals, Inc., H2 2011
Flamel Technologies S.A., H2 2011
Tolerx, Inc., H2 2011
XOMA Ltd., H2 2011
Lipoxen PLC, H2 2011
SemBiosys Genetics Inc., H2 2011
Uni-Bio Science Group Ltd., H2 2011
Kamada Ltd., H2 2011
DiaMedica Inc., H2 2011
CPEX Pharmaceuticals, Inc., H2 2011
Affimed Therapeutics AG, H2 2011
Bayhill Therapeutics, Inc., H2 2011
Phosphagenics Limited, H2 2011
Artielle ImmunoTherapeutics, Inc., H2 2011
ApoImmune, Inc., H2 2011
DiaKine Therapeutics, Inc., H2 2011
Peptimmune, Inc., H2 2011
Kineta, Inc., H2 2011
Creative Peptides Sweden AB, H2 2011
Andromeda Biotech Ltd., H2 2011
AIM Therapeutics Inc., H2 2011
NovImmune SA, H2 2011
Txcell SA, H2 2011
TcL Pharma SAS, H2 2011
Versartis, Inc., H2 2011
Virobay Inc., H2 2011
Immunomod, LLC, H2 2011
Exsulin Corporation, H2 2011
REGiMMUNE Corporation, H2 2011
TikoMed AB, H2 2011
Adocia, H2 2011
Diasome Pharmaceuticals, Inc., H2 2011
PharmaIN Corporation, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Type 1 Diabetes (Juvenile Diabetes) Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Type 1 Diabetes (Juvenile Diabetes), H2 2011
Products under Development for Type 1 Diabetes (Juvenile Diabetes) – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Note: Product cover images may vary from those shown
Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos